BioNTech Strengthens mRNA Portfolio with CureVac Acquisition

BioNTech has taken a decisive step to consolidate its position in the messenger RNA (mRNA) therapy sector by successfully completing its takeover of competitor CureVac. While this strategic expansion bolsters the company's long-term prospects, its shares continue to face technical headwinds in the market.

The tender offer for CureVac was finalized on December 18. BioNTech received 195.3 million CureVac shares, issuing 10,475,287 of its own American Depositary Shares (ADS) in exchange to the former CureVac shareholders. The exchange was executed at a fixed ratio of 0.05363 BioNTech ADS per CureVac share.

With this transaction, BioNTech now controls approximately 86.75% of CureVac's outstanding capital. The company intends to acquire the remaining shares via a squeeze-out procedure scheduled for January 2026. Following this, CureVac will be delisted from the Nasdaq exchange. For now, CureVac will continue its ongoing operations as BioNTech conducts a comprehensive strategic review.

Management and Integration Strategy

Concurrent with the deal's closure, BioNTech has assumed direct control of CureVac's leadership. The new board of the acquired entity consists of BioNTech CEO Prof. Ugur Sahin, COO Sierk Poetting, and CFO Ramón Zapata-Gomez. The previous CureVac executive team voluntarily stepped down.

BioNTech has outlined a measured integration approach. Existing operational structures will remain in place initially to avoid business disruption while in-depth strategic, operational, and scientific analyses are performed.

Financial Standing and Updated Guidance

BioNTech enters this integration phase from a position of considerable financial strength. The company reported liquid assets of €16.7 billion as of the end of the third quarter in 2025.

Q3 2025 Financial Highlights:
* Revenue: €1.52 billion
* Quarterly Net Loss: €28.7 million
* Earnings Per Share (EPS): -€0.12

Notably, BioNTech has raised its full-year 2025 revenue forecast. The guidance has been increased from a prior range of €1.7–2.2 billion to a new range of €2.6–2.8 billion. This upward revision was partly driven by a $1.5 billion milestone payment received from collaboration partner Bristol Myers Squibb in November.

Should investors sell immediately? Or is it worth buying BioNTech?

Oncology Pipeline Advances

A key strategic focus for BioNTech is deepening its oncology footprint. Recent clinical data highlights progress in two core programs:

• Pumitamig (BNT327): This bispecific antibody, developed with Bristol Myers Squibb, targets PD-L1 and VEGF-A. Phase 2 data presented in early December showed a 61.5% response rate in patients with triple-negative breast cancer.
• Gotistobart: Developed in partnership with OncoC4, this selective Treg modulator demonstrated clinically relevant overall survival benefits in pre-treated patients with squamous non-small cell lung cancer.

These results underscore the company's efforts to leverage its mRNA and antibody platforms more firmly within cancer therapeutics.

Market Sentiment and Technical Performance

Wall Street analysts present a mixed view on the stock. The average 12-month price target stands around $138, suggesting significant potential upside from current levels.

Recent Analyst Actions:
* Berenberg Bank: Raised price target to $155
* Jefferies: Maintained price target at $151
* HC Wainwright: Buy rating with a $140 target
* Morgan Stanley: Overweight rating with a $131 target

Despite these targets, the share price continues to trade below both its 50-day and 200-day moving averages, indicating persistent technical weakness even as the company makes strategic advances.

Year-to-Date Performance and Forthcoming Catalysts

BioNTech shares have declined approximately 18% since the start of the year. Over the past twelve months, the stock has traded between $81.20 and $129.27, reflecting substantial volatility throughout 2025. The company's current market capitalization is approximately $22 billion.

Investors are likely to focus on the next quarterly report, expected in early March 2026. This update is anticipated to provide the first detailed insights into the CureVac integration progress and updated timelines for the combined oncology and mRNA pipeline, offering a clearer view into the future earnings potential of the enlarged entity.